TB-500: The Fragment Standing In For a Better-Studied Protein

The short version

TB-500 is the commercial and research-community name for a synthetic, N-acetylated heptapeptide, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (Ac-LKKTETQ), seven amino acids corresponding to residues 17-23 of the much larger, naturally occurring protein Thymosin Beta-4 (Tβ4). That short stretch carries Tβ4's actin-binding motif, the part of the protein believed to drive cell migration, wound healing, and blood-vessel growth.

The chart note that matters most: most published efficacy research on this pathway used the full 43-amino-acid Tβ4 protein, not the 7-amino-acid fragment sold as TB-500. A 2010 Phase 1 trial gave 40 healthy volunteers intravenous full-length Tβ4 up to 1260 mg daily for two weeks and found it well tolerated with no serious adverse events ^[16], but that is a study of the parent protein. Whether the isolated fragment reproduces those results at typical research doses has not been established in a completed human trial. TB-500 is not FDA-approved, is prohibited in competitive sport, and no human dose is recommended on this page.

What it is

TB-500 is a synthetic, N-terminally acetylated heptapeptide (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH), corresponding to residues 17-23 of the endogenous 43-amino-acid protein Thymosin Beta-4 (gene TMSB4X). This LKKTETQ motif is the conserved actin-binding region shared across the beta-thymosin family. In commerce and in the analytical/anti-doping literature, 'TB-500' denotes this 7-amino-acid fragment specifically, sometimes also labeled TB-500 or TB1000 in veterinary contexts, but the large majority of the encouraging published efficacy research described below used the full-length protein (roughly 4963 Da), not the roughly 889 Da fragment. This notebook flags that identity distinction on every finding where it applies, because it changes how much of the literature genuinely applies to what is being sold.

How it works

Full-length Tβ4 is the major intracellular actin-sequestering protein in cells: it binds monomeric (G-) actin in a 1:1 ratio, capping both ends of the actin monomer to hold a buffered reserve of unpolymerized actin and regulate cytoskeletal dynamics, cell migration, and motility. X-ray crystallography at 2 Å resolution confirmed this 1:1 dual-end-capping mechanism directly, identifying the WH2 actin-interacting motif as the structural basis ^[17].

In animal injury models, Tβ4, and by extension the LKKTETQ fragment that carries its actin-binding motif, is associated with faster cell migration, angiogenesis, anti-inflammatory and anti-apoptotic signaling, reduced myofibroblast/scar formation, and recruitment of progenitor cells. In mouse hearts, Tβ4 formed a complex with PINCH and integrin-linked kinase (ILK) that activated the survival kinase Akt, promoting cardiac and endothelial cell migration and, after coronary-artery ligation, improving early myocyte survival and cardiac function ^[18]. Whether the isolated 7-mer fragment reproduces the full protein's effects at the doses typically used in peptide research has not been established in controlled human trials.

What the research shows

Musculoskeletal-peptide safety review. A 2026 Sports Medicine review of approved and unapproved peptide therapies for musculoskeletal injuries, listing TB-500/thymosin beta-4 alongside BPC-157, found favorable tissue-repair outcomes in animal models generally paired with scarce human safety data, potential for serious harm, and operation largely outside regulatory oversight ^[6].

Stroke model, full-length protein. In Wistar rats with induced stroke (embolic middle cerebral artery occlusion), intraperitoneal Tβ4 at 2 and 12 mg/kg, given 24 hours post-stroke, then every three days for four more doses, significantly improved neurological function from day 14 through day 56. Notably, 18 mg/kg gave no significant benefit, a non-monotonic dose-response the study used to model an optimal dose near 3.75 mg/kg ^[14].

Consolidated mechanism review. A 2012 review lays out Tβ4's actin-binding basis for cell mobilization and migration, its role in decreasing myofibroblast numbers (reducing scar formation), its release by platelets and macrophages after injury to limit apoptosis, inflammation, and microbial growth, and its angiogenic activity, the rationale behind clinical trials in dermal wounds, corneal injury, and heart/CNS repair ^[15].

Human Phase 1 safety trial, full-length protein. In a randomized, placebo-controlled Phase 1 study, 40 healthy volunteers (four cohorts of ten) received intravenous synthetic Tβ4 as a single dose followed by daily dosing for 14 days at 42, 140, 420, or 1260 mg. It was well tolerated, with only infrequent mild-to-moderate adverse events, no dose-limiting toxicities, and no serious adverse events; pharmacokinetics were dose-proportional, with half-life increasing at higher doses ^[16].

Structural biology. X-ray crystallography of a Tβ4-actin complex at 2 Å resolution confirmed the 1:1 G-actin sequestration mechanism via dual-end capping, identifying the WH2 motif as the structural basis for actin buffering ^[17].

Cardiac repair model. In mice, Tβ4 activated the PINCH-ILK-Akt survival pathway, promoted cardiac and endothelial cell migration, and, after coronary-artery ligation, enhanced early myocyte survival and improved cardiac function ^[18].

Wound-healing model. In a rat full-thickness wound model, topical or intraperitoneal Tβ4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, increased wound contraction by at least 11% by day 7, and raised collagen deposition and angiogenesis; as little as 10 picograms stimulated a 2-3-fold increase in keratinocyte migration in vitro ^[19].

Reported effects, cautions & safety

People using TB-500 for research purposes describe a benefit pattern centered on soft-tissue recovery. This paragraph is anecdotal, not clinical evidence — the fragment itself has no completed human efficacy trial behind it.

Reported benefits: the leading reason people say they use TB-500 is faster recovery from tendon, ligament, and muscle injuries, with stubborn soft-tissue problems described as returning to activity sooner than expected. Frequently reported alongside this: less joint pain and stiffness with better range of motion, and improved overall flexibility and mobility during training, often noticed around three to four weeks in. Occasionally reported: a general feeling of reduced inflammation or calmer post-workout soreness, better wound and skin healing, and, rarely, more or thicker hair growth over four to eight weeks.

Reported adverse effects: the most common complaint is a mild injection-site reaction (redness, swelling, or aching), usually gone within a day or two. Many report temporary tiredness or lethargy for a day or two, especially early in a so-called loading phase. Less often reported: head rush or brief headache after injecting, a short flu-like feeling, nausea (more with larger amounts), a heightened awareness of an existing injury, or temporary low mood.

Cited cautions from the clinical literature:

• Human safety in people is essentially unstudied for the fragment itself. No completed controlled human trial of the TB-500 heptapeptide exists for any use; a 2026 review found unapproved peptides like it carry potential for serious harm and operate largely outside regulatory oversight ^[6][16].
• A theoretical cancer / tumor-growth concern applies. The parent protein, thymosin beta-4, is overexpressed in several cancers and has been linked to tumor spread and to the blood-vessel growth that feeds tumors — the same pro-migration, pro-angiogenic actions proposed for tissue repair.
• TB-500 is banned in competitive sport. It is prohibited by the World Anti-Doping Agency at all times under peptide and growth-factor categories, and anti-doping labs have developed methods to detect it and its breakdown products ^[6].
• Reported benefits may overstate what the peptide actually does. In one instructive animal study, long-term thymosin beta-4 use in a muscular-dystrophy mouse model increased the number of regenerating muscle fibers but did not improve muscle strength, heart function, or fibrosis — more regeneration on paper did not translate into better function.
• TB-500 is a fragment, not the full protein, and it is risky to assume it behaves identically to full-length thymosin beta-4, which carries almost all of the encouraging efficacy data ^[15].
• Research-grade product quality is not guaranteed. Material sold as TB-500 is not made to medicine-grade standards, and identity, purity, and exact sequence can vary between suppliers.
• Theoretical, precautionary cautions also apply around bleeding, surgery, and clotting, and around use in pregnancy, breastfeeding, or young people, given the peptide's basic role in cell migration and blood-vessel growth — none of this has been studied in humans for TB-500 specifically.

Where it fits in the repair cascade

TB-500 leads this notebook because its parent molecule, full-length thymosin beta-4, carries the deepest human trial record of any compound covered here, a full Phase 1 safety study in 40 people ^[16], even as the fragment actually sold under the TB-500 name remains untested in a completed human trial of its own. It shares an angiogenesis mechanism with BPC-157, which is why both carry the same theoretical cancer caution, and it is one of the four ingredients inside KLOW, paired there with BPC-157, KPV, and GHK-Cu in a single vial that has never been tested as a combination. See the full comparison for how TB-500's identity-fragment caveat sets it apart from the other three entries.